Selank typical research dosing
Across the available literature, Selank is most commonly administered at 250–3000 mcg per dose, 2 time(s) per day, via nasal injection. Selank is most commonly used as an intranasal solution (0.15% concentration). Research protocols vary from 250 mcg to 3 mg per day divided into 2–3 intranasal administrations. Clinical studies in Russia used 250–900 mcg daily for anxiety disorders.
Selank unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 0.25 mg Selank vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 250 mcg | 1625 mcg | 3000 mcg |
|---|---|---|---|---|
| 1 mL | 250 mcg/mL | 100.0 units | 650.0 units | 1200.0 units |
| 2 mL | 125 mcg/mL | 200.0 units | 1300.0 units | 2400.0 units |
| 3 mL | 83 mcg/mL | 300.0 units | 1950.0 units | 3600.0 units |
| 5 mL | 50 mcg/mL | 500.0 units | 3250.0 units | 6000.0 units |
Selank cycle length
Most reported Selank protocols run 4 weeks on, then 2 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Selank half-life and timing
Selank has a half-life of approximately 0.033 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.